Platform Technology Partners’s PhaseBio Pharmaceuticals, Inc. Common Stock PHAS Stock Holding History

Platform Technology Partners’s Portfolio PHAS Stock Details PHAS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-231,900	Closed	-$41K	–	215
2022 Q3	$41K	Sell	231,900 -11,000	-5%	-$11.2K	0.02%	184
2022 Q2	$146K	Buy	242,900 +427	+0.2%	+$409	0.08%	173
2022 Q1	$320K	Sell	242,473 -9,250	-4%	-$15K	0.15%	143
2021 Q4	$657K	Buy	251,723 +22,500	+10%	+$68K	0.29%	88
2021 Q3	$713K	Sell	229,223 -150	-0.1%	-$501	0.32%	82
2021 Q2	$853K	Buy	+229,373	New	+$763K	0.35%	81
2020 Q4	$474K	Buy	141,025 +48,075	+52%	+$172K	0.23%	115
2020 Q3	$326K	Buy	92,950 +38,976	+72%	+$157K	0.2%	126
2020 Q2	$248K	Buy	53,974 +19,224	+55%	+$85.1K	0.17%	143
2020 Q1	$115K	Buy	+34,750	New	+$159K	0.1%	155

Other funds holding PHAS

DCM

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

HLA

Hamilton Lane Advisors Conshohocken, Pennsylvania $149M AUM 14.17% 1-Year Est. Return

IIA

IPG Investment Advisors San Diego, California $582M AUM 33.22% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Platform Technology Partners's PHAS Position: Q4 2022 in Review

Platform Technology Partners sold out of PhaseBio Pharmaceuticals, Inc. Common Stock (PHAS) in Q4 2022, closing a stake of 231,900 shares — an estimated $41K sold.

Platform Technology Partners first reported a position in PHAS in Q1 2020 and held it in 10 quarters. The position peaked at $853K in Q2 2021. 5 funds tracked by Wall St. Rank hold PHAS as of Q4 2022.

Platform Technology Partners reported no remaining PhaseBio Pharmaceuticals, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
Platform Technology Partners sold 231,900 PhaseBio Pharmaceuticals, Inc. Common Stock shares in Q4 2022, an estimated $41K.
Platform Technology Partners first reported a position in PhaseBio Pharmaceuticals, Inc. Common Stock in Q1 2020 and held it in 10 quarters.
Platform Technology Partners's PhaseBio Pharmaceuticals, Inc. Common Stock position peaked at $853K in Q2 2021.
5 funds tracked by Wall St. Rank held PhaseBio Pharmaceuticals, Inc. Common Stock as of Q4 2022.

Based on Platform Technology Partners's 13F filing for Q4 2022, filed 11 Jan 2023.